List of Excipients in Branded Drug NUVIGIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT Rx USA LLC	NUVIGIL	armodafinil	16590-345	CELLULOSE, MICROCRYSTALLINE
STAT Rx USA LLC	NUVIGIL	armodafinil	16590-345	CROSCARMELLOSE SODIUM
STAT Rx USA LLC	NUVIGIL	armodafinil	16590-345	LACTOSE MONOHYDRATE
STAT Rx USA LLC	NUVIGIL	armodafinil	16590-345	MAGNESIUM STEARATE
STAT Rx USA LLC	NUVIGIL	armodafinil	16590-345	POVIDONE

Nuvigil Excipient Strategy, Patent Exposure, and Commercial Opportunities

Last updated: September 24, 2026

Nuvigil is the branded formulation of armodafinil, a wakefulness-promoting agent approved by the FDA for excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift-work sleep disorder. Its tablet formulation uses conventional excipients, including lactose monohydrate, pregelatinized starch, croscarmellose sodium, povidone, magnesium stearate, and film-coating materials. The main commercial opportunity is not a differentiated excipient platform. It is the development of lower-cost, patient-specific, rapidly disintegrating, lactose-free, modified-release, and international formulations that preserve armodafinil exposure and tablet performance.

What excipients are used in Nuvigil tablets?

Nuvigil tablets contain armodafinil in four strengths: 50 mg, 150 mg, 200 mg, and 250 mg. The FDA labeling identifies conventional tablet excipients used for binding, disintegration, lubrication, and coating.

Formulation function	Publicly identified Nuvigil excipients
Diluent	Lactose monohydrate
Binder	Povidone
Disintegrant	Croscarmellose sodium
Filler and processing aid	Pregelatinized starch
Lubricant	Magnesium stearate
Film coating	Hypromellose, titanium dioxide, polyethylene glycol, and related coating components

The approved product is an immediate-release, film-coated tablet. The public label identifies qualitative excipient composition but does not disclose the quantitative amount of each excipient or the manufacturing process parameters. That distinction matters because generic manufacturers can use different excipient quantities or substitute excipients if they demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway.

Nuvigil’s formulation is technically conventional. Its performance depends on active-ingredient particle properties, blend uniformity, compression behavior, disintegration, dissolution, and consistent armodafinil exposure rather than on a proprietary delivery technology. (FDA, 2015; DailyMed, 2024)

What commercial opportunities exist for Nuvigil excipient suppliers?

The strongest opportunities are in excipient substitution, process optimization, and differentiated dosage forms.

Lactose-free armodafinil tablets

Lactose monohydrate is a cost-effective and widely used pharmaceutical diluent, but it creates a product-positioning issue for patients with lactose intolerance or for manufacturers seeking a fully lactose-free portfolio. Potential substitutes include:

• Microcrystalline cellulose
• Mannitol
• Dibasic calcium phosphate
• Spray-dried mannitol
• Coprocessed cellulose-based excipients
• Starch-based direct-compression systems

A lactose-free formulation would not automatically create regulatory exclusivity. Its commercial value would depend on a demonstrable benefit, such as improved patient acceptance, reduced gastrointestinal complaints, better compression performance, or supply-chain resilience.

Direct-compression platforms

Armodafinil tablets contain a relatively high active load at the 250 mg strength. A direct-compression excipient system could reduce granulation steps, shorten manufacturing time, and improve continuous manufacturing compatibility.

Coprocessed excipients may offer advantages in:

• Flowability
• Compactibility
• Reduced lubricant sensitivity
• Lower tablet weight
• Better content uniformity
• More consistent disintegration across strengths

The principal development risk is segregation between armodafinil particles and excipient particles. Particle-size distribution, density, electrostatic behavior, and mixing time can materially affect dose uniformity.

Orally disintegrating and orally dispersible tablets

An orally disintegrating formulation could target patients who have difficulty swallowing during wakefulness episodes, patients with irregular work schedules, or users seeking faster administration without water. Suitable excipient technologies include:

• Mannitol-based rapidly dissolving matrices
• Crospovidone or croscarmellose systems
• Taste-masking polymers
• Sublimation-based porous tablets
• Spray-dried carbohydrate matrices

Armodafinil has a bitter taste profile. Taste masking is therefore a central technical issue. Coating the drug particles, using ion-exchange approaches, or embedding armodafinil in a polymeric matrix could improve palatability. The formulation must avoid materially changing the rate or extent of armodafinil absorption unless the product is developed under a different regulatory strategy.

Modified-release formulations

A modified-release armodafinil product could target patients who need sustained wakefulness over a long work period or who experience adverse effects from peak concentrations. Potential technologies include hydrophilic matrix tablets, multiparticulate systems, coated pellets, and osmotic delivery.

The commercial opportunity is larger than for a conventional generic, but so is the clinical and regulatory burden. A modified-release product would require new pharmacokinetic characterization and could be regulated as a new drug product rather than as a simple abbreviated new drug application. Any change in exposure profile could affect insomnia, anxiety, headache, blood pressure, and drug-interaction risks. The product would need a clinically credible dosing rationale, not only a formulation rationale.

How does Nuvigil’s excipient strategy compare with Provigil?

Nuvigil contains armodafinil, the R-enantiomer of modafinil, while Provigil contains racemic modafinil. Both products use conventional oral-tablet technology.

Attribute	Nuvigil	Provigil
Active ingredient	Armodafinil	Modafinil
Stereochemistry	R-enantiomer	Racemic mixture
Dosage form	Immediate-release film-coated tablet	Immediate-release tablet
Main formulation opportunity	Differentiated armodafinil delivery	Modafinil cost reduction and alternative dosage forms
Excipient differentiation	Limited public evidence	Limited public evidence
Generic pathway	Armodafinil ANDA products	Modafinil ANDA products
Key technical challenge	Dose uniformity and exposure control	Dose uniformity and exposure control

Nuvigil’s commercial positioning historically depended more on active-ingredient differentiation and pharmacokinetic claims than on excipient innovation. That leaves room for competitors to compete through manufacturing efficiency, patient-centric dosage forms, and supply reliability.

What FDA regulatory status applies to armodafinil generic products?

Nuvigil was approved under NDA 021875. Armodafinil generics are generally developed through the FDA abbreviated new drug application pathway. A conventional immediate-release generic must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.

The relevant regulatory requirements include:

1. Matching the reference product’s active ingredient, strength, dosage form, and route of administration.
2. Demonstrating acceptable dissolution and product quality.
3. Establishing bioequivalence under FDA requirements.
4. Meeting current good manufacturing practice standards.
5. Providing information on inactive ingredients and manufacturing controls.
6. Addressing differences in colorants, flavors, preservatives, and other excipients.

Excipients can differ from the reference product. The difference becomes commercially relevant when it affects tolerability, dissolution, tablet robustness, stability, or patient acceptance. Inactive-ingredient changes also require regulatory review when the proposed ingredient or level raises safety concerns.

What patents protect Nuvigil and its formulation?

Nuvigil’s patent position historically centered on armodafinil and related pharmaceutical claims rather than a clearly differentiated excipient system. Publicly disclosed Nuvigil labeling does not establish that the listed excipients, individually or in their ordinary combinations, provide a strong proprietary barrier.

The relevant patent categories are:

Patent category	Relevance to Nuvigil
Armodafinil composition patents	Protect the active pharmaceutical ingredient or its chemical identity
Stereochemical or enantiomer claims	Protect the R-enantiomer relative to racemic modafinil
Pharmaceutical composition claims	May cover armodafinil with defined carriers or dosage forms
Solid-state or polymorph claims	May cover crystalline forms or physical properties
Method-of-use claims	May cover treatment of excessive sleepiness or related conditions
Manufacturing claims	May cover synthesis, purification, resolution, or crystallization
Excipient-specific claims	Appear less central to the conventional Nuvigil formulation

The patent strength of a conventional generic tablet is usually limited where the proposed product avoids protected solid forms, manufacturing processes, and formulation claims. The strongest potential barriers may arise from armodafinil solid-state claims, process patents, or later-developed dosage forms rather than from lactose, starch, povidone, or magnesium stearate.

When did Nuvigil lose exclusivity and what generic entry risks remain?

Nuvigil received FDA approval in June 2007. The reference product’s market exclusivity period expired before the current generic market developed, and multiple generic armodafinil products entered the U.S. market. Generic entry has substantially reduced the value of the conventional immediate-release product.

The remaining entry risks are concentrated in four areas:

• Product-specific patents that remain listed or enforceable.
• Patent claims covering armodafinil solid forms or manufacturing processes.
• Regulatory delays caused by bioequivalence or dissolution failures.
• Commercial barriers involving controlled-substance handling, supply, and wholesaler access.

Armodafinil is a Schedule IV controlled substance in the United States. Manufacturers and distributors must manage controlled-substance registration, quotas, recordkeeping, security, and diversion controls. Those obligations can increase the cost of market entry even when the core formulation is technically straightforward.

What Paragraph IV challenges and litigation affect Nuvigil?

Paragraph IV litigation risk arises when an ANDA applicant certifies that a listed patent is invalid, unenforceable, or not infringed. The Nuvigil generic market was shaped by patent challenges and settlements involving the branded product’s sponsor and generic applicants.

For current commercial planning, the relevant questions are narrower than the original launch litigation:

• Whether any patent remains listed for the reference product.
• Whether a generic applicant used a Paragraph IV certification.
• Whether litigation resulted in a stay of FDA approval.
• Whether a settlement imposed a delayed-entry date or other restrictions.
• Whether later formulation patents cover a modified-release or orally disintegrating product.

Settlement terms can affect launch timing, but the economic importance of legacy Nuvigil settlements has declined as multiple armodafinil products have entered the market. A new entrant is more likely to face ordinary generic competition and supply-chain pressure than a single-patent blockade.

What formulation patents could create new commercial value?

The most commercially relevant formulation claims would need to protect a measurable product advantage. Candidate claim areas include:

Orally disintegrating armodafinil

Potential claim elements include particle-size distribution, taste-masking coating, disintegration time, tablet porosity, and dissolution profile.

Pediatric or geriatric formulations

Liquid suspensions, mini-tablets, dispersible granules, and low-dose tablets could address populations poorly served by 50 mg and higher conventional tablets. Stability and dose uniformity would be central.

Low-dose titration products

A scored or multipart tablet system could improve dose titration for patients sensitive to stimulant-like adverse effects. The commercial value would depend on prescribing practices and payer coverage.

Extended-release products

A protected release profile could support a branded reformulation strategy if clinical data show reduced peak-related adverse effects or improved adherence.

Abuse-deterrent or controlled-substance handling systems

Armodafinil is lower risk than Schedule II stimulants, but tamper-resistant packaging and controlled-substance operational controls could support institutional or specialty distribution. Packaging claims would be more defensible than broad claims based only on ordinary excipients.

Which companies can compete in the armodafinil market?

Competition includes the former Nuvigil sponsor, generic pharmaceutical companies, contract manufacturers, and excipient suppliers.

Generic manufacturers can compete through:

• Lower cost of goods
• Reliable controlled-substance supply
• Multiple tablet strengths
• Dual-source excipient procurement
• Smaller minimum order quantities
• Hospital and specialty-pharmacy distribution
• International registrations

Excipient suppliers can compete by offering validated platforms rather than commodity materials. The most valuable commercial package would include formulation screening, compaction data, dissolution support, regulatory documentation, and supply assurance. A supplier that can replace lactose without sacrificing tablet strength or bioequivalence has a stronger proposition than a supplier offering an undifferentiated grade of starch or cellulose.

How strong is the Nuvigil patent estate?

The estate is materially weaker for conventional generic tablets than for new armodafinil delivery systems. The underlying active-ingredient and use patents created the original market barrier, but the conventional formulation relies on common excipients and standard immediate-release technology.

Patent factor	Assessment
Conventional excipient protection	Low
Immediate-release tablet differentiation	Low
Active-ingredient history	Historically significant
Manufacturing-process exposure	Product- and route-dependent
Modified-release opportunity	Potentially stronger
Orally disintegrating formulation opportunity	Potentially stronger
Generic entry barrier	Moderate operational barrier, lower formulation barrier
Biosimilar risk	Not applicable

Biosimilar competition does not apply because armodafinil is a synthetic small molecule, not a biologic. The relevant competitors are generic ANDA applicants and branded reformulation developers.

What revenue exposure does Nuvigil face from generic competition?

The conventional branded product faces substantial revenue compression after generic entry. Generic substitution is particularly strong for a tablet product with:

• No complex device component
• No biologic manufacturing requirement
• No injectable presentation
• No proprietary excipient platform disclosed in the label
• Established bioequivalence methodology
• Multiple approved strengths

Revenue can persist in narrow channels where prescribers prefer the branded product, patients report differences between manufacturers, or payer policies permit brand dispensing. A reformulated product would need a clear clinical or convenience benefit to support premium pricing.

Key Takeaways

• Nuvigil contains a conventional immediate-release armodafinil tablet formulation.
• The principal excipients are lactose monohydrate, pregelatinized starch, croscarmellose sodium, povidone, magnesium stearate, and film-coating materials.
• The strongest excipient opportunities are lactose-free tablets, direct-compression systems, orally disintegrating tablets, and modified-release products.
• Conventional excipient combinations provide limited standalone patent protection.
• Generic armodafinil competition has reduced the value of the original branded formulation.
• Modified-release and taste-masked dosage forms offer greater potential for new intellectual-property protection.
• Controlled-substance requirements remain an operational barrier despite the simplicity of the tablet technology.
• Biosimilar risk does not apply; the competitive threat comes from generic armodafinil manufacturers and branded reformulations.

FAQs About Nuvigil Excipients and Commercial Strategy

Can lactose be removed from Nuvigil without changing the active ingredient?

Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a coprocessed excipient system, subject to formulation development and FDA requirements.

Does Nuvigil have a proprietary excipient combination?

The public Nuvigil label identifies conventional pharmaceutical excipients. It does not establish a commercially differentiated excipient platform comparable to a lipid nanoparticle, osmotic pump, or long-acting injectable system.

Is an armodafinil orally disintegrating tablet patentable?

Potentially. Patentability would depend on the specific formulation, including taste masking, particle properties, disintegration performance, dissolution, stability, and demonstrated technical differences over prior art.

Are armodafinil products eligible for biosimilar approval?

No. Armodafinil is a synthetic small molecule. Generic armodafinil products use the ANDA pathway rather than the biosimilar pathway.

What is the best near-term commercial opportunity around Nuvigil?

A cost-efficient, lactose-free immediate-release tablet is the lowest-risk opportunity. An orally disintegrating or modified-release product offers greater differentiation but requires more extensive clinical, regulatory, and intellectual-property development.

References

1. DailyMed. (2024). Nuvigil- armodafinil tablet, film coated prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2015). Nuvigil (armodafinil) prescribing information. FDA.

3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2016). Inactive ingredient database. FDA.

5. U.S. Food and Drug Administration. (2013). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA.